253 related articles for article (PubMed ID: 31853477)
1. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease.
Galasko D; Xiao M; Xu D; Smirnov D; Salmon DP; Dewit N; Vanbrabant J; Jacobs D; Vanderstichele H; Vanmechelen E; ; Worley P
Alzheimers Dement (N Y); 2019; 5():871-882. PubMed ID: 31853477
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease.
Massa F; Martinuzzo C; Gómez de San José N; Pelagotti V; Kreshpa W; Abu-Rumeileh S; Barba L; Mattioli P; Orso B; Brugnolo A; Girtler N; Vigo T; Arnaldi D; Serrati C; Uccelli A; Morbelli S; Chincarini A; Otto M; Pardini M
J Neurol; 2024 Apr; 271(4):1999-2009. PubMed ID: 38157030
[TBL] [Abstract][Full Text] [Related]
3. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
[TBL] [Abstract][Full Text] [Related]
4. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.
Lleó A; Carmona-Iragui M; Videla L; Fernández S; Benejam B; Pegueroles J; Barroeta I; Altuna M; Valldeneu S; Xiao MF; Xu D; Núñez-Llaves R; Querol-Vilaseca M; Sirisi S; Bejanin A; Iulita MF; Clarimón J; Blesa R; Worley P; Alcolea D; Fortea J; Belbin O
Alzheimers Res Ther; 2021 Jun; 13(1):119. PubMed ID: 34183050
[TBL] [Abstract][Full Text] [Related]
5. NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
Soldan A; Oh S; Ryu T; Pettigrew C; Zhu Y; Moghekar A; Xiao MF; Pontone GM; Albert M; Na CH; Worley P
Ann Neurol; 2023 Oct; 94(4):620-631. PubMed ID: 37345460
[TBL] [Abstract][Full Text] [Related]
6. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
[TBL] [Abstract][Full Text] [Related]
7. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
[TBL] [Abstract][Full Text] [Related]
8. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
9. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
Dickerson BC; Wolk DA;
Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
[TBL] [Abstract][Full Text] [Related]
11. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
Nilsson J; Pichet Binette A; Palmqvist S; Brum WS; Janelidze S; Ashton NJ; Spotorno N; Stomrud E; Gobom J; Zetterberg H; Brinkmalm A; Blennow K; Hansson O
Brain; 2024 Feb; ():. PubMed ID: 38325331
[TBL] [Abstract][Full Text] [Related]
13. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
14. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease.
Xue M; Sun FR; Ou YN; Shen XN; Li HQ; Huang YY; Dong Q; Tan L; Yu JT;
Aging (Albany NY); 2020 May; 12(10):9365-9379. PubMed ID: 32421689
[TBL] [Abstract][Full Text] [Related]
15. Neuronal pentraxin 2 correlates with neurodegeneration but not cognition in idiopathic normal pressure hydrocephalus (iNPH).
Patel M; Zhang Y; Xiao MF; Worley P; Moghekar A
Neurol Neurochir Pol; 2024; 58(1):47-53. PubMed ID: 38393959
[TBL] [Abstract][Full Text] [Related]
16. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
Wang L;
Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum.
Goossens J; Cervantes González A; Dewit N; Lidón L; Fortea J; Alcolea D; Lleó A; Belbin O; Vanmechelen E
Alzheimers Res Ther; 2023 Oct; 15(1):186. PubMed ID: 37898760
[TBL] [Abstract][Full Text] [Related]
18. Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
Kling MA; Goodenowe DB; Senanayake V; MahmoudianDehkordi S; Arnold M; Massaro TJ; Baillie R; Han X; Leung YY; Saykin AJ; Nho K; Kueider-Paisley A; Tenenbaum JD; Wang LS; Shaw LM; Trojanowski JQ; Kaddurah-Daouk RF;
Alzheimers Dement; 2020 Sep; 16(9):1234-1247. PubMed ID: 32715599
[TBL] [Abstract][Full Text] [Related]
19. CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework.
Llano DA; Devanarayan P; Devanarayan V;
Neurobiol Aging; 2023 Jan; 121():15-27. PubMed ID: 36368195
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
Libiger O; Shaw LM; Watson MH; Nairn AC; Umaña KL; Biarnes MC; Canet-Avilés RM; Jack CR; Breton YA; Cortes L; Chelsky D; Spellman DS; Baker SA; Raghavan N; Potter WZ; ;
Alzheimers Dement; 2021 Dec; 17(12):1976-1987. PubMed ID: 33984181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
